Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: A phase II trial

Anti-Cancer Drugs

Volumn 19, Issue 5, 2008, Pages 527-533

  Amato, Robert J ^a,b   Jac, Jaroslaw ^a   Hernandez McClain, Joan ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Gefitinib; Imatinib; Interferon; Renal cell carcinoma; Tyrosine kinase inhibition

Indexed keywords

ALPHA2B INTERFERON; GEFITINIB; IMATINIB;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PAPILLOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; SURVIVAL RATE;

EID: 42349102912     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282fa4ad2     Document Type: Article

References (52)

1. SEERS stat fact sheet: cancer of the kidney and renal pelvis. http://www.seer.cancer.gov/statfacts/html/kidrp.html. [Accessed 13 July 2007].
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
3. Presti JC Jr, Rao PH, Chen Q, Reuter VA, Li FP, Fair WR, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 1991; 51:1544-1552.
4. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 1999; 162:1246-1258.
5. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976; 38:2469-2480.
6. Sene AP, Hunt L, McMahon RF, Carroll RN. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol 1992; 70:125-134.
7. Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 1995; 154:28-31.
8. Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2b plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-2867.
9. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143:468-473.
10. Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol Clin N Am 1993; 20:263-275.
11. Montie IB, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Uro1 1977; 117:272-275.
12. Muss HB, Costanzi II, Leavitt R, Williams RD, Kempf RA, Pollard R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Onco1 1987; 5:286-291.
13. Mani S, Todd MB, Katz K, Poo J. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:35-40.
14. Flanigan RC. Role of surgery in patients with metastatic renal cell carcinoma. Semin Urol Oncol 1996; 14:227-229.
15. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997; 158:1675-1678.
16. Wagner IR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999; 162:43-45.
17. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655-1659.
18. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-1076.
19. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:1928-1935.
20. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004; 4:455-468.
21. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma - predictors of response. Semin Oncol 2006; 33:583-587.
22. McDermott DF, Regan MM, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer 2006; 5:114-119.
23. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 2006; 107:2375-2383.
24. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141.
25. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
26. White RL, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74:3212-3222.
27. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alfa as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999; 22:145-154.
28. Horoszewicz JS, Murphy GP. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989; 142:1173-1180.
29. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1:CD001425.
30. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21:499-512.
31. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
32. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
33. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
34. Bhojani N, Jeldres C, Patard JJ, Percotte P, Suardi N, Huttere G, et al. Toxicities associated with administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2007; doi:10.1016/j.eururo.2007.11.037
35. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-36.
36. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55:401-423.
37. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44:879-894.
38. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109:2171-2181.
39. Lager DJ, Slagel DD, Palechek PL. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 1994; 7:544-548.
40. Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73:1913-1918.
41. Otani N, Tsukamoto T, Masumori N, Saiki I, Yoneda J, Kumamoto Y. Influence of growth factors on in vitro invasiveness and type IV collagenolysis of human renal cell carcinoma cells. J Urol 1994; 151:223-226.
42. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 1992; 52:3335-3339.
43. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
44. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004; 10:7812-7819.
45. Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21:341-345.
46. Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 2006; 57:533-539.
47. Vuky J, Isacson C, Fotoohi M, De La Cruz J, Otero H, Picozzi V, et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Investigational New Drugs 2006; 24:85-88.
48. Polite BN, Desai AA, Manchen B, Stadler WM. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single-institution phase II trial. Clin Genitourin Cancer 2006; 4:275-280.
49. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alpha-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25:3296-3301.
50. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
51. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
52. Fuhrman SA, Lasky LC, Limus C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-663.